SGEN Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
01:24
Jun 23
A May MD Biotech investor
Author defends Pfizer and related biotech names against activist Starboard but uses defensive.
Author defends Pfizer and related biotech names against activist Starboard but uses defensive language ("we need them", "careful") without stating a personal position or forward call.
SGEN
14:00
May 05 ◎
Dr. Albert Bourla Chairman & CEO, Pfizer, Inc. PFE Q1 FY26 call
Pfizer's Seagen acquisition is delivering strong oncology revenue growth, validating strategic investment in ADCs.
SGEN
HIGH
15:00
Feb 03 ◎
Dr. Chris Boshoff Chief Scientific Officer, Pfizer, Inc. PFE Q4 FY25 call
Seagen integration is successful, providing a robust pipeline (ADCs like PADSEV) and maintaining talent, positioning Pfizer for oncology growth.
SGEN
HIGH

About SGEN Analyst Coverage

Buzzberg tracks SGEN across 2 sources. 0 bullish vs 0 bearish calls from 3 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Latest voices: A May MD, Dr. Albert Bourla, Dr. Chris Boshoff.